In the case-control study, to evaluate the role of the KRAS-variant in predicting uterine cancer risk, allele data was obtained for 583 population controls, 430 patients with type 1 endometrial cancer and 37 patients with type 2 cancer. The gene discussed is KRAS; the disease is endometrial cancer.